These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 7940930)
41. Cytokine-release syndrome: differences between high and low doses of OKT3. Norman DJ; Kimball JA; Barry JM Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420 [No Abstract] [Full Text] [Related]
42. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group. Peeters P; Kazek M; Abella I; Noble I Transplant Proc; 1998 Aug; 30(5):1838-42. PubMed ID: 9723301 [No Abstract] [Full Text] [Related]
43. Successful therapy of chronic renal allograft failure by enhanced immunosuppression. Kliem V; Tiroke T; Ehlerding G; Eberhard O; Behrend M; Frei U; Koch KM; Pichlmayr R; Brunkhorst R Transplant Proc; 1998 Jun; 30(4):1207-9. PubMed ID: 9636490 [No Abstract] [Full Text] [Related]
44. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413 [TBL] [Abstract][Full Text] [Related]
45. OKT3/antithymocyte globulin immunoprophylaxis in the prevention of recurrence of acute vanishing bile duct syndrome in retransplanted patients. Gómez R; Moreno E; Colina F; Gonzalez I; Loinaz C; Garcia I; Luque I; Lumbreras C; Vega V; Moreno C Transplant Proc; 1994 Dec; 26(6):3701-5. PubMed ID: 7998325 [No Abstract] [Full Text] [Related]
46. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Cantarovich M; Latter DA; Loertscher R Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721 [TBL] [Abstract][Full Text] [Related]
47. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436 [TBL] [Abstract][Full Text] [Related]
48. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation? Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420 [No Abstract] [Full Text] [Related]
49. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation. Kitabayashi K; Munn SR; Sterioff S Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964 [No Abstract] [Full Text] [Related]
50. Favourable clinical results of Sandimmun-Neoral in malabsorbing liver and heart transplant recipients. Färber L; Maibücher A; Geissler F; Gutzler F; Wiesinger FO; Winkler M Transplant Proc; 1994 Oct; 26(5):2988-93. PubMed ID: 7940944 [No Abstract] [Full Text] [Related]
51. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? Wagner FM; Reichenspurner H; Uberfuhr P; Kur F; Kaulbach HG; Meiser BM; Ziegler U; Reichart B J Heart Lung Transplant; 1994; 13(3):438-42; discussion 442-3. PubMed ID: 8061020 [TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune. Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189 [No Abstract] [Full Text] [Related]
53. Cost-effective management of acute rejection in liver transplant recipients: a managed care perspective. Abouljoud MS; Brown KA; May E; Baliad P; Escobar FS; Mozes MF Transplant Proc; 1997; 29(1-2):1557-9. PubMed ID: 9123423 [No Abstract] [Full Text] [Related]
54. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. Knoop C; Antoine M; Vachiéry JL; Yernault JC; Estenne M Transplant Proc; 1994 Dec; 26(6):3240-1. PubMed ID: 7527957 [No Abstract] [Full Text] [Related]
55. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. Melter M; Rodeck B; Kardorff R; Hoyer PF; Maibücher A; Brodehl J Transplant Proc; 1996 Aug; 28(4):2276-8. PubMed ID: 8769224 [No Abstract] [Full Text] [Related]
56. Use of antilymphocyte induction therapy in liver transplantation: A European perspective. Langrehr JM; Neuhaus PJ Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S71-84. PubMed ID: 10431020 [No Abstract] [Full Text] [Related]
58. The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. Torre-Cisneros J; Mañez R; Kusne S; Alessiani M; Martin M; Starzl TE Transplant Proc; 1991 Dec; 23(6):3040-1. PubMed ID: 1721353 [No Abstract] [Full Text] [Related]
59. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation. Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207 [No Abstract] [Full Text] [Related]